Skip to main content

ROIV

Stock
Health Care
Biotechnology

Performance overview

ROIV Price
Price Chart

Forward-looking statistics

Beta
0.37
Risk
34.23%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.

Company info

SectorHealth Care
IndustryBiotechnology
Website—
Employees608
Market cap$7.7B

Fundamentals

Enterprise value$3.4B
Revenue$29.1M
Revenue per employee—
Profit margin96.86%
Debt to equity1.93

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.75
Dividend per share—
Revenue per share$0.04
Avg trading volume (30 day)$76M
Avg trading volume (10 day)$104M
Put-call ratio—

Macro factor sensitivity

Growth+1.0
Credit+3.1
Liquidity-1.9
Inflation-1.3
Commodities+1.6
Interest Rates-3.0

Valuation

Dividend yield0.00%
PEG Ratio-9.24
Price to sales257.15
P/E Ratio-9.24
Enterprise Value to Revenue116.14
Price to book1.63

Upcoming events

Next earnings dayMay 29, 2025
Next dividend day—
Ex. dividend day—

News

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.16.

Zacks Investment Research (May 29, 2025)
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

OrganonĀ & Co OGN has agreed to acquire Roivant Sciences Ltd's ROIV Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.

Benzinga (September 18, 2024)
A biotech firm founded by Vivek Ramaswamy turned $15 million into $5 billion by flipping a bowel-disease treatment that Pfizer gave it for free

Roche acquired a bowel-disease treatment from Roivant for over $7 billion, the Wall Street Journal reported. Roivant made $5 billion from the sale, after having only spent $15 million on development. Pfizer originally passed it over to Roivant for free last December.

Business Insider (October 24, 2023)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free